DiaSorin, a specialist IVD player, is set to enter its next growth cycle driven by recent/ upcoming product launches. Moreover, an installed base business model and improving product mix should augment the group’s industry-leading margin profile. Consistently increasing the dividend flow and net cash position further enhances its appeal. Top this up with the extraordinary demand for COVID-19 solutions, the fundamentally robust business is worth considering at current levels.
23 Sep 2020
A niche diagnostic player
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A niche diagnostic player
DiaSorin S.p.A. (DIAS:WBO) | 0 0 2.6% | Mkt Cap: 4,042m
- Published:
23 Sep 2020 -
Author:
Sumit Sayal -
Pages:
52
DiaSorin, a specialist IVD player, is set to enter its next growth cycle driven by recent/ upcoming product launches. Moreover, an installed base business model and improving product mix should augment the group’s industry-leading margin profile. Consistently increasing the dividend flow and net cash position further enhances its appeal. Top this up with the extraordinary demand for COVID-19 solutions, the fundamentally robust business is worth considering at current levels.